Monday, November 13, 2023 10:27:32 PM
However, I think the much bigger lost opportunity was an inability to license the technology to much larger companies with huge revenues from existing products that already utilized SVM. I blame Intel for that lost opportunity. It is extremely likely that the ongoing legal battles with Intel prevented some or most companies from agreeing to a licensing deal. Neogenomics did agree to license the technology but they are probably the exception. Even with Neogenomics choosing to license the tech, many other companies may have decided to wait until the outcome of the legal battle with Intel was known. Also, if I recall correctly, Neogenomics and HDC treated the arrangement more as a partnership with a shared expert - was it Dr Albitar? - working on the product.
I also don’t know if we ever found out why the biomarker test with Quest never panned out as expected. Did the patent dispute put that test on ice? I can’t remember so I could be wrong. I just remember that we had a superior prostate cancer test but for some reason Quest never rolled it out.
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM